ARS Pharmaceuticals (SPRY) Accumulated Expenses (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 6 years of Accumulated Expenses data on file, last reported at $5.8 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses changed N/A year-over-year to $5.8 million; the trailing twelve-month figure through Mar 2026 stood at $5.8 million (changed N/A YoY), and the FY2025 full-year result was $4.6 million, up 146.74% from the prior year.
• Accumulated Expenses rose to $5.8 million in Q1 2026, from $4.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $12.0 million in Q4 2022 to a low of $404000.0 in Q1 2022.
• A 4-year average of $3.7 million and a median of $2.1 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses tumbled 93.03% in 2022 and surged 146.74% in 2025, its largest moves.
• Tracing SPRY's Accumulated Expenses over 4 years: stood at $12.0 million in 2022, then tumbled by 84.54% to $1.9 million in 2024, then soared by 146.74% to $4.6 million in 2025, then climbed by 27.66% to $5.8 million in 2026.
• Business Quant data shows SPRY's Accumulated Expenses at $5.8 million in Q1 2026, $4.6 million in Q4 2025, and $1.7 million in Q3 2025.